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Promptly and accurately diagnosing genital-tract infections is key to instituting appropriate 
treatment and control of sexually transmitted infections (STIs). Ano-genital tract testing for 
STIs in the last two decades has not entirely moved away from insensitive methods but is 
now at least dominated by highly sensitive molecular methods. These tests can be ordered 
through the internet for use at home, with self-taken specimens then returned, usually by post, 
to a clinic or laboratory for testing. The increasing ease of access of the public to this 
situation, together with increasing online health–seeking behaviour, has resulted in a gap 
between commercial and NHS management pathways for STIs. Crucially, patients who order 
multiplex test kits on-line for use at home, and other non–specialists, may not realize that it is 
worthwhile testing only for Neisseria gonorrhoeae, Chlamydia trachomatis, and possibly 
Trichomonas vaginalis, and Mycoplasma genitalium  if the person is symptomatic or their 
current partner is infected. The detection and recommended treatment of micro-organisms 
which to some extent are part of the genital-tract microbiome, such as Mycoplasma hominis, 
Ureaplasma spp. or Gardnerella vaginalis, which do not cause symptoms in the majority of 
those infected, cannot be recommended. We argue that a shift from specialist led to patient 
and non–specialist led STI management, in the presence of a clinical leadership vacuum, has 
increased the risk of inappropriate and unnecessary treatment which will drive macrolide, 
tetracycline and metronidazole antimicrobial resistance. However, in the past 5-6 years 
several groups have been able to show the value of on-line testing as a consequence of 
targeting the most important micro-organisms and using molecular tests to allow rapid and 
appropriately informed treatment. This should herald a brighter future, although there is still a 
need for leadership to expertly guide commercial and NHS sectors alike. In turn, this requires 




dedicated genito-urinary medicine (GUM) commissioning to be maintained at a time when it 
appears to be most under threat.  
Introduction 
We previously gave an historical account of tests used to diagnose six sexually transmitted 
bacterial infections, and one protozoal, up to the advent of molecular  tests.1 These have now 
overtaken almost all others  at a time when the digital era has seen a revolution in health-
seeking behaviour with an unprecedented growth in the commercial market for STI tests. The 
public may now seek testing and treatment at home with information and access provided 
online, sometimes without involvement of a STI specialist or NHS provider. Seemingly, this 
would appear laudable, but it has some unwanted pitfalls. Here, we consider these together 
with the molecular tests and the impact that the molecular revolution is having on the 
sexually transmitted disease (STD) field. 
Observations on molecular diagnostic tests for the microbes under discussion   
Neisseria gonorrhoeae. Currently, the molecular tests used most often to detect  N. 
gonorrhoeae are those also set up to detect C.trachomatis in the same sample. These are  the 
nucleic acid amplification tests (NAATs) based on a polymerase chain reaction (PCR), 
namely Roche AMPLICOR and COBAS AMPLICOR; 2 one based on strand displacement  
amplification (BDProb Tec; Becton Dickinson) 3 and one based on transcription-mediated 
amplification (TMA): APTIMA Combo 2 (Gen-ProbeInc.).4 The cobas CT/NG v2.0 test 
(Roche Molecular Systems) 5 behaves comparably to the others mentioned, as does the new  
Abbott m2000 Real Time CT/NG assay.6 The  GeneXpertCT/NG assay (Cepheid, Sunnyvale, 
CA), with similar performance to the aforementioned NAATs produces a result within 1.5 
hours.  All these methods offer excellent sensitivity, usually well above 90%, while 
maintaining very high specificity. It is recommended that laboratories confirm any reactive 




test with an alternative molecular target if the positive predictive value of the initial test for 
the population tested is less than 90%.7 
Chlamydia trachomatis. The licensed NAATs for the detection of C.trachomatis are  those 
mentioned above for the detection of N.gonorrhoeae. All four assays, as said before, are 
highly specific and sensitive. Furthermore, where resources are limited, pooling of specimens 
from different individuals can reduce costs without loss of sensitivity.8 The formerly often 
used Abbott LCx ligase chain reaction test 9 was withdrawn from the market by the 
manufacturer in 2003.10 In 2013, the GeneXpertCT/NG assay (Cepheid, Sunnyvale, CA) 11 
was the first rapid NAAT shown to have attributes equivalent to recognized commercial 
NAATs. Therefore, it had the potential for use as a point-of-care (POC) test (vide infra) and 
for revolutionizing genitourinary infection diagnostics.12, 13 Recent attention has focused on 
pooling specimens from the pharynx, rectum and urogenital tract of the same individual at 
risk of infection in all three sites. This may perform better for detecting C. trachomatis than 
N.gonorrhoeae, but more data are needed for firm conclusions.12, 13  
Mycoplasma hominis. Real-time PCR technology for M.hominis was  described first  in   
2004 14  and, although not always of real-time construction, the PCR has subsequently been 
an integral part of numerous multiplex tests.15  Whether they should be used at all is discussed 
below.  
Gardnerella vaginalis. Early molecular studies 16, 17 showed that G.vaginalis belongs to a 
much  larger group of bacterial species that are associated with bacterial vaginosis (BV)  than 
was considered in the pre-molecular era. BV is characterised by depletion of key 
Lactobacillus spp., with an increase in bacterial species diversity and load, including that by 
Gardnerella vaginalis, Atopobium vaginae and other BV- associated bacteria (BVAB).18-22 
Atopobium vaginae  is more strongly associated with BV than G.vaginalis, the latter 
detectable by a NAAT in many asymptomatic women.18 -22  Therefore, detecting G.vaginalis 




without considering its load and  changes in the composition of other bacteria in the vaginal 
microbiome cannot be used to accurately diagnose BV. Becton Dickinson 23 have designed 
and validated a ‘vaginitis NAAT’ which uses an algorithmic analysis of molecular DNA 
detection of lactobacilli and four BVAB, including G.vaginalis,  Atopobium vaginae and 
Megasphaera spp., to diagnose BV with a sensitivity and specificity of  >90%, although a 
study in the UK using the Hay-Ison criteria revealed a specificity of only 79%.23      
 
Ureaplasma spp. Thirty-eight or more years after detection and quantification of  
 
ureaplasmas by culture, detection, speciation and quantification became possible by using  
 
PCR-based tests.24-27 Two species can be identified, namely Ureaplasma urealyticum and 
 
U.parvum. Ureaplasma spp. are common in the lower genital tract with a greater 
 
U.urealyticum bacterial load, in some men with non-gonococcal urethritis. 26, 28 
 
Subsequently, real-time multiplex tests for Ureaplasma spp., M.hominis and other micro- 
 
organisms were devised. Whether such tests should be used is considered below.  
 
Mycoplasma genitalium. Subsequent to the difficulty in isolating and culturing 
M.genitalium, DNA probes were tried, but these proved insufficiently sensitive. Then in the 
late 1980s, two groups 29, 30 each developed a PCR test that was much more sensitive.  Each 
amplified different fragments of the MgPa adhesin protein and showed that as little as 10-15 g 
of M.genitalium DNA could be detected This prompted others to use this technique and some 




to devise modifications, use a multiplex PCR, target the 16SrRNA gene of M.genitalium, and 
use TMA with success.31   Molecular methods have also shown an increase in the prevalence 
of M.genitalium resistance to several antibiotics, particularly macrolides (vide infra).32  The 
latter is probably due to extensive use of azithromycin 1g to treat chlamydial infections and 
non-gonococcal urethritis.32 There are now at least two satisfactorily sensitive, FDA-
approved, commercial assays, available, namely the Aptima TMA assay (Hologic Ltd) 33 and 
the Speedx ResistancePlus MG assay which also tests for macrolide resistance.34 The new 
guidelines 32  of the British Association for Sexual Health and HIV (BASHH) for 
M.genitalium   recommend testing patients with urethritis and pelvic inflammatory disease, 
and current sexual contacts and, if positive, testing for macrolide resistance-mediating 
mutations. This will improve clinical outcomes and reduce the risk of resistance to both 
macrolides and quinolones in the United Kingdom. There is no recommendation to screen 
asymptomatic individuals.  
Trichomonas vaginalis. Although some non-molecular diagnostic tests, for example, the  
OSOM rapid test,35 are used for convenience, NAATs out-perform all others.36 Thus, the 
TMA-based APTIMA TV test 37, 38, although not the only molecular one,39 is highly sensitive, 
FDA-approved and widely used, particularly as it fits into settings where gonococcal and 
chlamydial molecular tests are in place. Becton Dickenson have developed a multiplex 
format for simultaneous detection of N.gonorrhoeae and C.trachomatis which performs well 
in accurately detecting all three infections.40 The TV assay has also been incorporated in its 
vaginitis assay with no apparent loss in performance.41 
Issues around point-of-care (POC) tests 
A POC test has come to mean one in which a specimen is examined in a sensitive and rapid 
procedure close enough to the patient to let treatment begin with little waiting. We have 
mentioned before 1 that efforts to produce a rapid, specific and sensitive non-molecular POC 




test for C.trachomatis failed, largely due  to inadequate sensitivity. Furthermore, the notion 
by some that a test with a sensitivity less than desired, but allowing rapid treatment, is 
preferable to a slower NAAT of greater sensitivity belongs firmly to a bygone era. The view 
that POC tests should increasingly form the diagnostic approach of the future,42   has gained 
greater credibility due to the development of rapid NAATs. Modelling suggests that the 
introduction of such technology in sexual health clinics, including targeted multiplex testing, 
could be cost effective, and clinical evidence to support this is beginning to emerge. 43-45 
Thus, the GenXpert CT/NG molecular test when used  on asymptomatic patients attending a 
rapid testing service (Dean Street Express) provided results, compared with those for patients 
attending an existing sexual health clinic, that were faster and enabled faster treatment, fewer 
partner transmissions and reduced clinic costs due to fewer partner attendances.46 The same 
molecular test has also been used successfully when conducted routinely as a POC test by 
clinicians in remote primary healthcare settings.47 Looking to the future, these POC tests will 
also be able to detect antimicrobial resistance, enabling diagnosis and individualised 
treatment at the first health care visit, potentially reducing selection pressure on 
recommended antimicrobials, reducing  transmission of resistant strains and providing a 
means of surveying resistance. 48 Thus, the introduction of POC testing seems admirable if 
clinicians are fully aware of the complexities of treatment and can provide it quickly, 
knowing that it is based on an accurate microbiological diagnosis.  
 
Multiplex test dilemma 
Outside the NHS, there is increased testing by the public. They are vulnerable to multiplex 
assays being relatively cheap and to a commercial imperative to do as much testing as 
possible but, doubtless, bewildered by assays for as many as 12 different micro-
organisms/conditions. Some companies recommend testing for asymptomatic infections and 
most suggest treatment for all subjects with positive results. The notion that the public, 




without considerable help, can choose the correct tests and receive appropriate treatment is 
beyond imagination. Several commercial multiplex NAATs, which include detection for 
gonococcal and chlamydial infections, are available and CE marked. However, it is a concern 
that there is very limited comparative information in peer reviewed journals for most 
promoted assays regarding their performance in detecting these infections.  Further comments 
about multiplex tests for Ureaplasma spp., G.vaginalis and other microbes are made later. 
 
Home on-line screening and treatment 
 
Diagnostic and treatment services of apparent merit 
 
In view of the previous comments, it may seem ironic to say that better involvement of the 
public in their own care should be a laudable approach to tackling the increasing existence of 
STDs; home-based tests should empower the individual. Furthermore, it cannot be denied 
that the increased use of on-line services in the UK and elsewhere. 49 should theoretically help 
to ease the tension in understaffed and underfunded NHS GUM clinics. In the last dozen 
years, particularly in the last five to six, there has been a variety of on-line providers 50-55 that 
have supported screening and treatment services above and beyond those provided by 
attending NHS clinics. Success is attributable to the in-put of both physician and laboratory 
staff and to pin-pointing micro-organisms regarded as the most important. Thus, 
N.gonorrhoeae and C.trachomatis detection using NAATs has almost always been a feature 
and, usually, serology to diagnose syphilis and HIV infection. It is imperative that as the 
provision of on-line testing continues to expand, only appropriate testing and treatment are 
recommended and that there is a move away from promoting testing for micro-organisms for 
which there is no evidence that testing does more  good than harm, so increasing the risk of 
antimicrobial resistance. Commercial on-line testing may also compromise an understanding 
of the true prevalence of infection by public health authorities, unless they are mandated to 




contribute anonymised data to the national STI and HIV statistics produced by Public Health 
England.  
New diagnostic NAATs will include POC tests which will enable assessment of antimicrobial 
resistance, and multiplex options too 48. The most recent example is that for M.genitalium 
with macrolide resistance testing, the use of which has been shown to prevent the emergence 
of antimicrobial resistance in this mycoplasma.32 However, funding for such tests is a major 
concern, given the decrease in funding for sexual health services (vide infra). 
 
Screening and treatment services with apparent flaws 
 
Tests for the micro-organisms detailed above are accessible ‘on-line’ from innumerable 
commercial web-sites. These can be offered as both screening and diagnostic tests. This easy 
access to molecular testing for the public has resulted in a gap between the commercial and 
NHS diagnostic testing pathways. The public who initiate testing on-line should be aware that 
poorly performing, insensitive, POC tests for C.trachomatis, seen repeatedly for close on a 
decade, 56  still exist. These “CE approved” tests, including that for gonorrhoea, are most 
often lateral flow immunoassays providing a result within 10-15 minutes. This  implies an 
inferior sensitivity to molecular tests.57, 58 Promotional material suggests that the accuracy of 
some tests is >98%, although what limited external validation against a NAAT there is 59 
indicates a performance substantially below that stated in the package insert.58 Such tests can 
be purchased on-line in the United Kingdom and internationally 60 and are cheaper than the 
home-based NAATs (see above). The current commercial multiplex assays where specimens 
are sent to a laboratory for testing may be relatively cheap, but the wide range of different 
micro-organisms (up to 12) represented in the ‘one size fits all’ test profiles may attract the 
biggest market, rather than have the best clinical application. The public should be advised 
that testing is only worthwhile for N.gonorrhoeae and C.trachomatis, and in women possibly 
T.vaginalis, which has been reported to cause infection only rarely in the UK,  although 




associated with black minority ethnicity and deprivation in some parts.61 M.genitalium is also 
worth testing for 62, but only if the patient is symptomatic or their current partner is infected. 
Screening of asymptomatic men cannot be recommended in the absence of randomized 
controlled trials demonstrating cost effectiveness. 63 The need for controlled trials before 
screening for M,genitalium can be advised is also seen, for example, in women with 
reproductive problems.64 This note of caution contrasts with the notion that there is little or 
no need to test for the presence of some other micro-organisms. Thus, M.hominis has never 
been shown to cause urethritis or other significant disease in men and its recovery from the 
vagina, cervix or urine is very difficult to relate to any problem in the upper genital tract.65  
While a strong association with BV is undoubted, it has never been shown to be a cause in 
itself. Also, a positive test for Ureaplasma spp. in asymptomatic men and women does not 
deserve attention. However, testing for U.urealyticum may be appropriate in men with 
symptoms and signs of urethritis 66 although only if indisputable pathogens have been 
excluded and the organism load is large, as this species is probably only causal in 20-60% 
when it is associated with a high load.28, 67 In women, as is the case for M.hominis, detection 
of either Ureaplasma spp. in the vagina, cervix or urine has never been related significantly to 
a problem in the upper genital tract, or to the painful bladder syndrome, the urethral 
syndrome or infertility.68 A positive role for ureaplasmas in chronic lung disease of extremely 
low birth-weight infants has some support, 68, 69 but evidence for their involvement in preterm 
delivery is less convincing 68 despite a report 70 of a more promising association based on 
aggressive antibiotic therapy. Nevertheless, in both lung disease and premature delivery 
nothing has been published to justify routine antibiotic therapy to prevent mother to baby 
transmission. Whether large, rather than small, numbers of these organisms might be 
associated with any of the diseases mentioned is a logical but insufficiently tested notion. 
Hence, until there are definitive answers, there is no logic in screening or testing 




asymptomatic or symptomatic men and women for M.hominis, U.urealyticum or U.parvum, 
unless, of course, ureaplasmas are being sought as part of a research investigation. Indeed, the 
expert view 28 is that it is unquestionably inappropriate to treat just because these organisms 
have been detected in the lower genital tract. Nevertheless, there are commercial services 
currently recommending treatment with doxycycline, azithromycin and both sequentially 
when these micro-organisms are detected in single assays or as part of a multiplex array. 
Thus, the virtue of having these tests available on-line must be questioned, particularly as it is 
known that antibiotics may dramatically change the gut and oral microbiomes 71 and 
doubtless the genital-tract microbiome too. So far as G.vaginalis is concerned, there seems 
little point in having it alone in a multiplex array for diagnosing BV when other bacteria, 
mentioned above, are more strongly associated with BV. A molecular test 72 that takes into 
account various bacteria encountered in BV would seem to have more merit. Of course, tests 
on vaginal smears for their cellular composition 73, 74 is a laboratory undertaking without 
patient involvement at home.  
The issues considered are important because a positive PCR test may fuel fears of infection 
and infectivity among the public and health professionals alike. This is particularly so if 
reference is made to sexually transmitted infection / disease 75 and when positivity may  not  
mean that the micro-organism in question is responsible for the symptoms and, therefore,  
may not imply treatment. Antibiotics may offer false assuagement of resultant patient 
distress. Not understanding  what antibiotic is required 76 or failing to take heed of  
management guidelines for  non-gonococcal urethritis, 77, 78 N.gonorrhoeae 79 or 
M.genitalium,80  and/or a lack of understanding that M.hominis, U.urealyticum and U.parvum 
can be difficult to eradicate, may have an untoward outcome, namely over-prescribing or  
providing a wrong antibiotic when the need for effective antibiotic stewardship is an 
international priority. The extensive treatment for the latter microbes, mainly commensals, 




with suboptimal antimicrobial regimens selects for resistance not only in them, but also in 
N.gonorrhoeae and M.genitalium. Thus, although a novel electronic messaging treatment 
service for C.trachomatis at a community pharmacy with the use of azithromycin 1g 81  might 
seem attractive, it has to be weighed against fostering macrolide-resistance in M.genitalium. 
Indeed, the spectre of high-grade resistance by gonococci to macrolides 82 and most recently 
to both azithromycin and ceftriaxone 83 and  M.genitalium  to  macrolides  and  other 
antibiotics 84-92 is with us. In the case of the latter micro-organism, pristinomycin may be the 
only antibiotic effective for some patients.93 It is not surprising to learn that syndromic 
management may fail 94 and empiric treatment needs to be reconsidered 95, 96 as a result of 
antimicrobial resistance. 97 Furthermore, increasingly led by non-specialists, commercial 
services may sometimes not involve a GUM specialist until repeated courses of antibiotics 
lead to iatrogenic harm, including antibiotic-associated candidiasis.This must not be allowed 
to continue. A micro-organism already antibiotic resistant or that has developed resistance 
during treatment may not be catered for adequately. Although it is theoretically possible that 
prolonged sub-inhibitory concentrations of azithromycin intra- and extra-cellularly after 
treatment of a gonococcal infection leads to resistance, evidence that previous exposure leads 
to resistance by this means is conflicting.98, 99 This is in contrast to M.genitalium, the 
resistance of  which, as noted, is influenced in this way. 
What should be done? 
It is imperative that inappropriate and unnecessary testing for sexually transmitted micro-
organisms by commercial on-line companies needs to be regulated to ensure that there is a 
move away from promoting increased antimicrobial resistance. Achieving this can be helped 
by educating the public, particularly those with self-diagnosis and treatment in mind, as to 
what is right and wrong by information provided simply, both on-line and in clinics, and by 
maintaining GUM commissioning with a remit to lead and disseminate NICE-accredited 




guidance for both the commercial and NHS sectors. The crucial nature of this is emphasized 
by the fact that on the 13th July 2018 the British Association of Sexual Health and HIV 
(BASHH) launched new NICE-accredited treatment guidelines for M,genitalium 32 in an 
attempt to prevent it becoming a ‘superbug’ within 10 years. At the same time, however, 
seven in ten sexual health experts said they could not afford diagnostic tests recommended by 
the guidelines and only one in ten UK public health commissioners said they were making 




First, for those who intend that diagnosis should start at home, the aim should be procurement 
of appropriate specimens that are sent under guided instruction to laboratories equipped with 
rapid and highly sensitive tests, followed by physician-guided treatment. In some areas in the 
UK and elsewhere an on-line approach to diagnosis and treatment has been developed to good 
effect and these ventures should be seen as role models for others in the field. The use of very 
rapid NAATs 11, 46, 100 must be a virtue, but speed associated with such a POC test may be less 
important than having a knowledgeable and thoughtful approach to treatment based on the 
correct laboratory result; the latter should be aided by adherence to the appropriate BASHH 
guideline. 7, 32 Second, it might appear that the issues are being discussed without positive 
action being taken.  However, it would be churlish to believe this when one of us (PH) attended 
a Parliamentary Roundtable meeting on Sexual Health and AMR (3rdApril 2019).101 
Nevertheless, further thought should be given to how expert clinical leadership can be 
improved with a view to regulatory change. There should be a multi-agency approach involving 
key stakeholders with the remit to guard against the use of insensitive and inappropriate tests 
and help to maintain further improvements in the diagnostic scene. Thus, it would be laudable 
to discourage testing for M.hominis, G.vaginalis, and Ureaplasma spp., when positive results 
have little or no meaning, unless the person is male and has urethritis and quantitative testing 




for U.urealyticum is available. Third, it would seem appropriate to develop NHS-accredited 
information leaflets for providers and the public on the use of molecular tests, the significance 
of results and the most appropriate treatment. Certainly, on-line self-diagnosis has improved, 
but pitfalls mentioned here should not go unchecked. There is still an opportunity to further 
harness molecular diagnostics towards best patient care, good medical practice, improved 
research and avoidance of further antibiotic resistance. Fourthly, with increasing antibiotic 
resistance of N.gonorrhoeae and M.genitalium in mind, efforts should be made to encourage 
the development and testing of  
vaccines.102, 103   Prevention is better than cure.    
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